Glenmede Trust’s PTC Therapeutics PTCT Stock Holding History

Glenmede Trust’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-40	Closed	-$1K	–	1992
2020 Q3	$1K	Hold	40	–	–	﹤0.01%	2382
2020 Q2	$2K	Buy	+40	New	+$1.97K	﹤0.01%	2259

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Glenmede Trust's PTCT Position: Q4 2020 in Review

Glenmede Trust sold out of PTC Therapeutics (PTCT) in Q4 2020, closing a stake of 40 shares — an estimated $1K sold.

Glenmede Trust first reported a position in PTCT in Q2 2020 and held it in 2 quarters. The position peaked at $2K in Q2 2020. 214 funds tracked by Wall St. Rank hold PTCT as of Q4 2020.

Glenmede Trust reported no remaining PTC Therapeutics position as of Q4 2020 after selling out during the quarter.
Glenmede Trust sold 40 PTC Therapeutics shares in Q4 2020, an estimated $1K.
Glenmede Trust first reported a position in PTC Therapeutics in Q2 2020 and held it in 2 quarters.
Glenmede Trust's PTC Therapeutics position peaked at $2K in Q2 2020.
214 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.